Business Context and Reporting Period
Company: NewAmsterdam Pharma Company N.V.
Filing Type: Form 8-K (Current Report)
Date of Report: May 7, 2026
Reporting Period: Quarter ended March 31, 2026
Context: The filing announces corporate updates and financial results for the first quarter of 2026 via a press release furnished as Exhibit 99.1.
Key Financial Metrics
The provided text is a cover page and index for the Form 8-K. It references a press release containing the financial data but does not include the specific numerical values within this document.
- Revenue: Not provided in this text.
- Profit/Loss: Not provided in this text.
- Cash Flow: Not provided in this text.
- Margins: Not provided in this text.
- Debt and Liquidity: Not provided in this text.
Material Changes
The filing text does not provide specific data to compare against the prior comparable period. It only confirms that results for the quarter ended March 31, 2026, were announced.
Guidance, Outlook, and Risks
Management Commentary: The Company issued a press release on May 7, 2026, regarding corporate updates and Q1 2026 results. The specific content of this commentary is contained in Exhibit 99.1, which is not included in the input text.
Legal Disclaimer: The information in Item 2.02 and Exhibit 99.1 is "furnished" and not "filed" under the Exchange Act. It is not subject to Section 18 liability and will not be incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated May 7, 2026) for actual revenue, net income, and cash position figures.
- Verify the specific "corporate updates" mentioned in the press release to understand operational changes.
- Confirm the status of the Company's ordinary shares (NAMS) and warrants (NAMSW) trading on The Nasdaq Stock Market LLC.
- Check subsequent filings for the full financial statements if the press release only provides highlights.